Given that Russias pharmaceutical market is expected to grow by 9% towards 2017, reaching an estimated RUB 823.629 billion (USD 17.6 billion at the exchange rate from Q4 2014), Russia is a promising country for investment. This will encourage both the innovative growth of the pharmaceutical industry and the qualitative improvement of medicinal provisions for Russian patients. What are the prospects for Russias pharmaceutical market under these current conditions? How can available reserves from the partnerships between the government and the pharmaceutical industry be used to solve problems for the provision of healthcare and medicines? How can new opportunities be grasped? What stimuli will help achieve the planned targets of government programmes in the healthcare, pharmaceutical and medical industries? What influence do the regional integration processes in the EAEU have on Russias pharmaceutical market?